Patent
Cellular basis of vascular-graft stenosis
| العنوان: | Cellular basis of vascular-graft stenosis |
|---|---|
| Patent Number: | 624,893& |
| تاريخ النشر: | June 19, 2001 |
| Appl. No: | 09/188,081 |
| Application Filed: | November 06, 1998 |
| مستخلص: | A mouse model for vein graft stenosis useful for identifying compounds which reduce or prevent such stenosis, consisting of a mouse engrafted with an autogenous vein which exhibits detectable stenosis within 30 days of transplantation. Also disclosed are therapeutic methods for inhibiting the development of vein graft stenosis. |
| Inventors: | Haber, Edgar (late of Salisbury, NH); Shi, Chengwei (Short Hills, NJ); Sibinga, Nicholas E. S. (Cambridge, MA) |
| Assignees: | President and Fellows of Harvard College (Cambridge, MA) |
| Claim: | What is claimed is |
| Claim: | 1. A mouse model for vein graft stenosis, said model comprising a recipient mouse comprising a vein patch surgically transplanted from a histocompatible donor mouse into a defect in an artery of said recipient mouse, wherein graft stenosis occurs within 30 days of transplantation. |
| Claim: | 2. The model of claim 1, wherein said vein patch is autologous. |
| Claim: | 3. The model of claim 1, wherein said vein patch is derived from a jugular vein. |
| Claim: | 4. The model of claim 1, wherein said artery is a carotid artery. |
| Claim: | 5. The model of claim 1, wherein said mouse is of the C57BL/6J strain. |
| Claim: | 6. The model of claim 1, wherein said recipient mouse has a knockout mutation in the gene encoding plasminogen. |
| Claim: | 7. An in vivo screening assay to determine whether a compound reduces vein graft stenosis, comprising |
| Claim: | (a) providing a first mouse comprising a first vein patch autogenously transplanted into an artery of said mouse; |
| Claim: | (b) providing a second mouse histocompatible with said first mouse, said second mouse comprising a second vein patch autogenously transplanted into an artery of said second mouse; |
| Claim: | (c) contacting said artery of said first mouse with a candidate compound either before or after autogenous transplantation of said first vein patch; and |
| Claim: | (d) comparing (1) the degree of vein graft stenosis in said artery of said first mouse which occurs within 30 days after transplantation of said artery, with (2) the degree of vein graft stenosis in said artery of said second mouse which occurs within 30 days after transplantation of said second artery, wherein a lesser degree of vein graft stenosis in said first artery compared to said second artery is an indication that said candidate compound reduces vein graft stenosis. |
| Claim: | 8. The screening assay of claim 7, wherein said candidate compound is an inhibitor of macrophage activity. |
| Claim: | 9. The screening assay of claim 7, wherein said candidate compound is an inhibitor of CD4-positive T cell activity. |
| Claim: | 10. The screening assay of claim 7, wherein said candidate compound is an inhibitor of B cell activity. |
| Claim: | 11. The screening assay of claim 7, wherein said candidate compound inhibits vascular smooth muscle cell proliferation. |
| Claim: | 12. The screening assay of claim 7, wherein said vein is a jugular vein and said artery is a carotid artery. |
| Claim: | 13. An in vivo screening assay to determine whether a plasminogen gene encodes a gene product that decreases vein graft stenosis, comprising |
| Claim: | (a) providing a first mouse and a second mouse, wherein said first mouse lacks a functional copy of said gene and said second mouse comprises at least one functional copy of said gene, said first mouse further comprising a vein patch autogenously transplanted into an artery of said first mouse and said second mouse further comprising a second vein patch autogenously transplanted into an artery of said second mouse; |
| Claim: | (b) comparing the degree of vein graft stenosis in the transplanted artery in said first mouse and second mouse, wherein an increase in vein graft stenosis in said first mouse compared to said second mouse indicates that the gene product decreases vein graft stenosis. |
| Claim: | 14. An in vivo screening assay to determine whether a plasminogen gene encodes a gene product that increases vein graft stenosis, comprising |
| Claim: | 15. An in vivo screening assay to determine whether a compound reduces vein graft stenosis, comprising |
| Claim: | (d) comparing (1) the degree of vein graft stenosis in said first artery of said mouse which occurs within 30 days after transplantation of said artery, with (2) the degree of vein graft stenosis in said second artery of said second mouse which occurs within 30 days after transplantation of said second artery, wherein a lesser degree of vein graft stenosis in said first artery compared to said second artery is an indication that said candidate compound reduces vein graft stenosis. |
| Claim: | 16. A method of making a mouse comprising a vein graft stenosis, said method comprising |
| Claim: | (a) providing a recipient mouse; and |
| Claim: | (b) engrafting a vein patch from a histocompatible donor mouse into an artery of said recipient mouse, wherein graft stenosis occurs within 30 days of transplantation. |
| Claim: | 17. The method of claim 16, wherein said vein patch is derived from a jugular vein and said artery is a carotid artery. |
| Claim: | 18. The method claim 16, wherein said artery is a carotid artery. |
| Claim: | 19. The method of claim 16, wherein said vein patch is derived from a jugular vein. |
| Current U.S. Class: | 800/18; 800/3; 800/9; 800/13; 800/14; 800/18; 424/92; 424/569; 435/11; 4353/201; 600/36 |
| Current International Class: | A01K 67027; A01K 67033; A61K 4900; A61K 3534; A01N 100 |
| Patent References Cited: | 5675062 October 1997 Haber et al. |
| Other References: | McCann et al. Artery. 6(4): 267-79, 1980.* Feldman et al. Fundamentals of Clinical Pharmacology. 9: 8-16, 1995.* Koveker et al. Surgery. 109: 313-9, Mar. 1991.* Carmeliet et al. Journal of Clinical Investigation. 99(2): 200-208, Jan. 1997.* Bryan et al. Current Opinion in Cardiology. 9(6): 641-9, Nov. 1994.* Zwolak et al. Arteriosclerosis, 9(3): 374-9, May 1989.* Faries et al. Journal of Vascular Surgery. 24(3): 463-471, 1986.* Mullins et al. J Clin Investigation. 98(11): S37-40, Dec. 1996.* Palmiter et al. Ann. Rev. Genet. 20: 465-99, May 1989.* Moreadith et al. J Mol Med 75: 208-216, May 1989.* Zou et al., "Mouse Model of Venous Bypass Graft Arteriosclerosis", American Journal of Pathology, 153:1301-1310, 1998. Betsholtz, "Role of platelet-derived growth factors in mouse development", The International Journal of Developmental Biology, 39:817-825, 1995. Carmeliet et al., "Gene Targeting and Gene Transfer Studies of the Biological Role of the Plasminogen/Plasmin System", Thrombosis and Haemostasis, 74:429-36, 1995. Carmliet et al., "Impaired Arterial Neointima Formation in Mice with Disruption of the Plasminogen Gene", The Journal of Clinical Investigation, 99:200-208, 1997. Cubitt et al., "Differential Induction of GRO.alpha. Gene Expression in Human Corneal Epithelial Cells and Keratocytes Exposed to Proinflammatory Cytokines", Investig. Ophthalmalogy & Visual Sci., 38:1149-1158, 1997. Czubayko et al., "Ribozyme-targeting Elucidates a Direct Role of Pleiotrophin in Tumor Growth", The Journal of Biological Chemistry, 269:21358-21363, 1994. Gao et al., "Impaired Host Defense, Hematopoiesis, Granulomatous Inflammation and Type 1-Type 2 Cytokine Balance in Mice Lacking CC Chemokine Receptor 1", The Journal of Experimental Medicine, 185:1959-1968, 1997. Kobayashi et al., "Reversal of Drug Sensitivity in Multidrug-Resistant Tumor Cells by an MDR1 (PGY1) Ribozyme", Cancer Research, 54:1271-1275, 1994. Nakamuta et al., "Complete Phenotypic Characterization of apobec-1 Knockout Mice with a Wild-type Genetic Background and a Human Apolipoprotein B Transgenic Background, and Restoration of Apolipoprotein B mRNA Editing by Somatic Gene Transfer of Apobec-1", The Journal of Biological Chemistry, 271:25981-25988, 1996. Roder et al., "The beige mutation in the mouse selectively impairs natural killer cell function", Nature, 278:451-453, 1979. Russell et al., "Early and persistent induction of monocyte chemoattractant protein 1 in rate cardiac allografts", Proceedings of the National Academy of Sciences (USA), 90:6086-6090; 1993. Russell et al., "Identification and Upregulation of Galactose/N-acetylgalactosamine Macrophage Lectin in Rat Cardiac Allografts with Arteriosclerosis", The Journal of Clinical Investigation, 94:722-730, 1994. Schultz et al., "Genetically Determined Murine Models of Immunodeficiency", Ann. Rev. Immunol., 5:367-403, 1987. Stevenson et al., "Phenotypic Correction of Hypercholesterolemia in ApoE-Deficient Mice by Adenovirus-Mediated In Vivo Gene Transfer", Arteriosclerosis, Thrombosis and Vascular Biology, 15:479-484, 1995. Sullivan, "Development of Ribozymes for Gene Therapy", The Journal of Investigative Dermatology, 103:85s-89s, 1994. Wang et al., Human Recombinant Macrophage Inflammatory Protein-1.alpha. and-.beta. and Monocyte Chemotactic and Activating Factor Utilize Common and Unique Receptors on Human Monocytes, J. Immunol., 150:3022-3029, 1993. Watanabe et al., "Mice deficient in cystathionine .beta.-synthase: Animal models for mild and severe homocyst(e)inemia", Proceedings of the National Academy of Sciences (USA), 92:1585-1589, 1995. Wiktor-Jedrzejczak et al., "Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse", Proceedings of the National Academy of Sciences (USA), 8:4828-4832, 1990. Xu et al., "Human Apolipoprotein E2, E3, and E4 Isoform-Specific Transgenic Mice: Human-Like Pattern of Glial and Neuronal Immunoreactivity in Central Nervous System Not Observed in Wild-Type Mice", Neurobiology of Disease, 3:229-245, 1996. Yoshida et al., "The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene", Nature, 345:442-444, 1990. |
| Primary Examiner: | Clark, Deborah J. R. |
| Assistant Examiner: | Stroup, Carrie |
| Attorney, Agent or Firm: | Beattie, Ingrid A. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
| رقم الانضمام: | edspgr.0624893. |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |